MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


SkinBioTherapeutics launces skin health research programme with University of Manchester

StockMarketWire.com

Skin health company SkinBioTherapeutics is to launch a research programme with the University of Manchester to investigate and develop microbiome formulations that support natural anti-inflammatory response to a range of environmental challenges.

Expanding the collaboration with the University was one of the areas of investment laid out by the company when it raised funds via placing and open offer in October 2020.

The programme, which will run for two years, will focus on how the microbiome can influence and rebalance the body's response to inflammation in skin health and skin disease.

Subject to a positive programme outcome, the company intends to pursue commercialisation of any identified bacterial formulations through their addition to existing third-party products or the development of new products targeted at specific conditions.

Professor Cath O'Neill, CSO of SkinBioTherapeutics said: There is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health.

The Company is in the middle of a food supplement study and the potential modifying effect on skin conditions, such as psoriasis. However, with this new line of research, we have the opportunity to assess the powerful effect of the microbiome on the immune system and skin health.

At 9:02am: (LON:SBTX) SkinBioTherapeutics Plc share price was 0p at 14.75p


Story provided by StockMarketWire.com